Venus Remedies gets additional US patent nod for Vancoplus

Drug firm Venus Remedies today received additional patent approval from United States Patent and Trademark Office (USPTO) for its product 'Vancoplus', used for treating bacterial infections.

"Venus Remedies already has product patent for Vancoplus from USPTO. This additional patent with broader coverage for use and method of treatment will be beneficial for the company," Venus Remedies said in a filing to BSE.

The patent is valid till 2032 and the company has already initiated pre-Investigational New Drug meeting with US health regulator, it added.

Vancoplus is a highly effective remedy to control Methicillin-resistant Staphylococcus aureus (MRSA), VRSA (Vancomycin Resistance Staphylococcus aureus) and other bacterial infections.

Global anti-bacterial market is slated to reach around USD 64 billion by 2018, Venus Remedies said.

Shares of Venus Remedies were trading at Rs 302.80 per scrip in the afternoon trade on BSE, up 0.26 per cent from its previous close.

EDITORIAL OF THE DAY

  • Saffronites need to build their own edifices and narratives

    The news that the BJP-led NDA government, no admirers of India’s first prime minister, want to give a ‘contemporary’ look to the capital’s mos

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Sachin Shridhar

Crouching tiger, hidden dragon

The Chinese are consummate gamblers. If you visit a casino ...

Zehra Naqvi

Capturing change

The pace of change in the world around us can ...

Gautam Gupta

Bring on the Benares brigade

It was in 2003 when I first started work and ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture